Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04

AUTHORS

Masahiro Kizaki, Naoto Takahashi, Noriyoshi Iriyama, Shinichiro Okamoto, Takaaki Ono, Noriko Usui, Koiti Inokuchi, Chiaki Nakaseko, Mineo Kurokawa, Masahiko Sumi, Fumihiko Nakamura, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Itaru Matsumura, Tomoki Naoe, the New TARGET investigators

ABSTRACT

We report the results of a multicenter observational study using the New TARGET system, in which the effectiveness and safety of tyrosine kinase inhibitors (TKIs) were evaluated in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. A total of 506 patients were enrolled between April 2010 and March 2013. Median age was 56 (range 18-92) years; 35% of patients were females. As the first-line therapy, 139 (27.9%), 169 (33.9%) and 144 (28.9%) patients were treated with imatinib, nilotinib, and dasatinib, respectively. Five-year progression-free survival (PFS) and overall survival (OS) were 93.8% and 94.5%, respectively. The OS curve was significantly superior for patients treated with second-generation TKIs than imatinib (P = 0.0068), and an early molecular response (EMR) at 3 months (BCR-ABL1 < 10%) was detected in 328 of 377 patients evaluated for molecular response. The PFS curve was significantly superior for patients with EMR than without (P < 0.0001). Although 12 patients experienced vascular adverse events, no new safety issues were observed in patients with adverse events. The results of this observational study demonstrated that treating newly diagnosed CML-CP patients with TKI results in satisfactory and reliable outcomes. More... »

PAGES

426-439

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-019-02613-1

DOI

http://dx.doi.org/10.1007/s12185-019-02613-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112098317

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30762219


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Jichi Medical University Saitama Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.415020.2", 
          "name": [
            "Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kizaki", 
        "givenName": "Masahiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Akita University", 
          "id": "https://www.grid.ac/institutes/grid.251924.9", 
          "name": [
            "Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Akita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Naoto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nihon University", 
          "id": "https://www.grid.ac/institutes/grid.260969.2", 
          "name": [
            "Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iriyama", 
        "givenName": "Noriyoshi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Keio University", 
          "id": "https://www.grid.ac/institutes/grid.26091.3c", 
          "name": [
            "Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okamoto", 
        "givenName": "Shinichiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hamamatsu University", 
          "id": "https://www.grid.ac/institutes/grid.411951.9", 
          "name": [
            "Division of Hematology, Department of Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ono", 
        "givenName": "Takaaki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Jikei University", 
          "id": "https://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Usui", 
        "givenName": "Noriko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nippon Medical School", 
          "id": "https://www.grid.ac/institutes/grid.410821.e", 
          "name": [
            "Department of Hematology, Nippon Medical School, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inokuchi", 
        "givenName": "Koiti", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chiba University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Department of Hematology, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakaseko", 
        "givenName": "Chiaki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tokyo", 
          "id": "https://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kurokawa", 
        "givenName": "Mineo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nagano Red Cross Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416382.a", 
          "name": [
            "Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sumi", 
        "givenName": "Masahiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Center For Global Health and Medicine", 
          "id": "https://www.grid.ac/institutes/grid.45203.30", 
          "name": [
            "Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakamura", 
        "givenName": "Fumihiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kumamoto Health Science University", 
          "id": "https://www.grid.ac/institutes/grid.411151.1", 
          "name": [
            "Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawaguchi", 
        "givenName": "Tatsuya", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shimane University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412567.3", 
          "name": [
            "Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Ritsuro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aichi Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Kazuhito", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Japanese Red Cross Society, Japan", 
          "id": "https://www.grid.ac/institutes/grid.410775.0", 
          "name": [
            "Japanese Red Cross Aichi Blood Center, Seto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohnishi", 
        "givenName": "Kazunori", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kindai University", 
          "id": "https://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Kindai University Faculty of Medicine, Osaka-Sayama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumura", 
        "givenName": "Itaru", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nagoya Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.410840.9", 
          "name": [
            "National Hospital Organization Nagoya Medical Center, Nagoya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naoe", 
        "givenName": "Tomoki", 
        "type": "Person"
      }, 
      {
        "familyName": "the New TARGET investigators", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/leu.2012.85", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006724216", 
          "https://doi.org/10.1038/leu.2012.85"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-09-594432", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008526384"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.64.8899", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015564810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa062867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018371941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428194.2015.1091929", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018642418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2015.5932", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020032457"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2016-01-694265", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021246169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-06-511592", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024126321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1002315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031069177"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0186-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035994537", 
          "https://doi.org/10.1007/s12185-008-0186-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0186-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035994537", 
          "https://doi.org/10.1007/s12185-008-0186-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-03-490128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037321453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2016.5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041273297", 
          "https://doi.org/10.1038/leu.2016.5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0912614", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044250877"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.leukres.2010.10.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045774124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-017-2208-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084034348", 
          "https://doi.org/10.1007/s12185-017-2208-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-017-2208-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084034348", 
          "https://doi.org/10.1007/s12185-017-2208-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1609324", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084149625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085249344"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-017-2353-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092351625", 
          "https://doi.org/10.1007/s12185-017-2353-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-018-3412-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105144477", 
          "https://doi.org/10.1007/s00277-018-3412-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04", 
    "datePublishedReg": "2019-04-01", 
    "description": "We report the results of a multicenter observational study using the New TARGET system, in which the effectiveness and safety of tyrosine kinase inhibitors (TKIs) were evaluated in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. A total of 506 patients were enrolled between April 2010 and March 2013. Median age was 56 (range 18-92) years; 35% of patients were females. As the first-line therapy, 139 (27.9%), 169 (33.9%) and 144 (28.9%) patients were treated with imatinib, nilotinib, and dasatinib, respectively. Five-year progression-free survival (PFS) and overall survival (OS) were 93.8% and 94.5%, respectively. The OS curve was significantly superior for patients treated with second-generation TKIs than imatinib (P\u2009=\u20090.0068), and an early molecular response (EMR) at 3\u00a0months (BCR-ABL1\u2009<\u200910%) was detected in 328 of 377 patients evaluated for molecular response. The PFS curve was significantly superior for patients with EMR than without (P\u2009<\u20090.0001). Although 12 patients experienced vascular adverse events, no new safety issues were observed in patients with adverse events. The results of this observational study demonstrated that treating newly diagnosed CML-CP patients with TKI results in satisfactory and reliable outcomes.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12185-019-02613-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "109"
      }
    ], 
    "name": "Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system", 
    "pagination": "426-439", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-019-02613-1"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "68816fc27b947596e0dfd34708bcb759109d1ff3202696adab0faa7cc7d247ef"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112098317"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9111627"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30762219"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-019-02613-1", 
      "https://app.dimensions.ai/details/publication/pub.1112098317"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56196_00000006.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs12185-019-02613-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02613-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02613-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02613-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02613-1'


 

This table displays all metadata directly associated to this object as RDF triples.

279 TRIPLES      21 PREDICATES      48 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-019-02613-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N810f711ee2354b83b80c9a177543c87c
4 schema:citation sg:pub.10.1007/s00277-018-3412-8
5 sg:pub.10.1007/s12185-008-0186-0
6 sg:pub.10.1007/s12185-017-2208-2
7 sg:pub.10.1007/s12185-017-2353-7
8 sg:pub.10.1038/leu.2012.85
9 sg:pub.10.1038/leu.2016.5
10 https://doi.org/10.1001/jamaoncol.2015.5932
11 https://doi.org/10.1016/j.leukres.2010.10.027
12 https://doi.org/10.1056/nejmoa062867
13 https://doi.org/10.1056/nejmoa0912614
14 https://doi.org/10.1056/nejmoa1002315
15 https://doi.org/10.1056/nejmoa1609324
16 https://doi.org/10.1093/annonc/mdx219
17 https://doi.org/10.1182/blood-2013-03-490128
18 https://doi.org/10.1182/blood-2013-06-511592
19 https://doi.org/10.1182/blood-2014-09-594432
20 https://doi.org/10.1182/blood-2016-01-694265
21 https://doi.org/10.1200/jco.2015.64.8899
22 https://doi.org/10.3109/10428194.2015.1091929
23 schema:datePublished 2019-04
24 schema:datePublishedReg 2019-04-01
25 schema:description We report the results of a multicenter observational study using the New TARGET system, in which the effectiveness and safety of tyrosine kinase inhibitors (TKIs) were evaluated in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. A total of 506 patients were enrolled between April 2010 and March 2013. Median age was 56 (range 18-92) years; 35% of patients were females. As the first-line therapy, 139 (27.9%), 169 (33.9%) and 144 (28.9%) patients were treated with imatinib, nilotinib, and dasatinib, respectively. Five-year progression-free survival (PFS) and overall survival (OS) were 93.8% and 94.5%, respectively. The OS curve was significantly superior for patients treated with second-generation TKIs than imatinib (P = 0.0068), and an early molecular response (EMR) at 3 months (BCR-ABL1 < 10%) was detected in 328 of 377 patients evaluated for molecular response. The PFS curve was significantly superior for patients with EMR than without (P < 0.0001). Although 12 patients experienced vascular adverse events, no new safety issues were observed in patients with adverse events. The results of this observational study demonstrated that treating newly diagnosed CML-CP patients with TKI results in satisfactory and reliable outcomes.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N40407fffc2ff494484825a2c60cc5140
30 N824090a70e064c278fee07212b6ce2d5
31 sg:journal.1076985
32 schema:name Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system
33 schema:pagination 426-439
34 schema:productId N9780ecb35843487bac190108420a8c77
35 Nde1877191e034782a85f4a7b53ec5d24
36 Ne65173af4d4943e7a1277c08b137aca4
37 Nf77bd17b90b944959621a7f1cb20761d
38 Nfd8bf465fb294b1a92b7198d40650b0a
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112098317
40 https://doi.org/10.1007/s12185-019-02613-1
41 schema:sdDatePublished 2019-04-15T09:28
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher N42bbe074780c474fbc844455a1ab92a7
44 schema:url https://link.springer.com/10.1007%2Fs12185-019-02613-1
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N11d3039ef25e457ca37c1dd21d93b41b rdf:first N9fb522e0fd9b4936b3c1d6a25f0165c7
49 rdf:rest N949802c4ad814291a6b31d39b04cf0b9
50 N1bb9ba3c4dab4135b7faa29f075d9ca7 rdf:first N6c559a330dc14a388155387148e95bad
51 rdf:rest Nbf1c334259304173a3a26fbfb6c8fae7
52 N1db06506afcd4f5d977228c8c9477350 rdf:first Nab6a7f7d7b364eafaacb1b9d62b172f6
53 rdf:rest N1bb9ba3c4dab4135b7faa29f075d9ca7
54 N1f07c3862f46475da522441d0b96d7af schema:affiliation https://www.grid.ac/institutes/grid.410840.9
55 schema:familyName Naoe
56 schema:givenName Tomoki
57 rdf:type schema:Person
58 N2039f4a1288d44708b20bce29a70c1b4 rdf:first Nf8b77d805f3c4abbab4a754fec5f2647
59 rdf:rest N716c8f5c78fb48eba6a34135a954dfb4
60 N243a3697b8f549179be328d86b5c886e schema:affiliation https://www.grid.ac/institutes/grid.251924.9
61 schema:familyName Takahashi
62 schema:givenName Naoto
63 rdf:type schema:Person
64 N2e0c98e86e7948f184f18f008536e515 schema:affiliation https://www.grid.ac/institutes/grid.411321.4
65 schema:familyName Nakaseko
66 schema:givenName Chiaki
67 rdf:type schema:Person
68 N309e85716455495fa5fbcf1899a551ac schema:affiliation https://www.grid.ac/institutes/grid.258622.9
69 schema:familyName Matsumura
70 schema:givenName Itaru
71 rdf:type schema:Person
72 N40407fffc2ff494484825a2c60cc5140 schema:issueNumber 4
73 rdf:type schema:PublicationIssue
74 N422b23b07e0244868d3df4cd5d92a949 schema:affiliation https://www.grid.ac/institutes/grid.412567.3
75 schema:familyName Suzuki
76 schema:givenName Ritsuro
77 rdf:type schema:Person
78 N42bbe074780c474fbc844455a1ab92a7 schema:name Springer Nature - SN SciGraph project
79 rdf:type schema:Organization
80 N449601592fa147729aca84026b6215e9 schema:affiliation https://www.grid.ac/institutes/grid.411951.9
81 schema:familyName Ono
82 schema:givenName Takaaki
83 rdf:type schema:Person
84 N5d07cbd5603f4806bfb696bff6127656 rdf:first Nf746cb43873842eca5928565a9d0aa06
85 rdf:rest N621005e4e0984d1e87850ad3820fa58f
86 N621005e4e0984d1e87850ad3820fa58f rdf:first Nc48c2a5c7c7d4e0a826156346e08a4ee
87 rdf:rest Nbf4f38cdce4f4946bc6f52fea435af7c
88 N6457f22486e5406b802b67e7ca3400f7 schema:affiliation https://www.grid.ac/institutes/grid.415020.2
89 schema:familyName Kizaki
90 schema:givenName Masahiro
91 rdf:type schema:Person
92 N6c559a330dc14a388155387148e95bad schema:affiliation https://www.grid.ac/institutes/grid.26091.3c
93 schema:familyName Okamoto
94 schema:givenName Shinichiro
95 rdf:type schema:Person
96 N716c8f5c78fb48eba6a34135a954dfb4 rdf:first N422b23b07e0244868d3df4cd5d92a949
97 rdf:rest N5d07cbd5603f4806bfb696bff6127656
98 N79fd958a6c4f4dad84eab5cf3b5ac470 rdf:first N2e0c98e86e7948f184f18f008536e515
99 rdf:rest Nd3185fe611084959acdb4af9126ccb30
100 N810f711ee2354b83b80c9a177543c87c rdf:first N6457f22486e5406b802b67e7ca3400f7
101 rdf:rest N8a8e0c6501c94920901bdfbf0bf01767
102 N824090a70e064c278fee07212b6ce2d5 schema:volumeNumber 109
103 rdf:type schema:PublicationVolume
104 N864a578ebc774c68980434d20b23fb0a rdf:first Nb5ba568191144b0fb9e6038fb384e046
105 rdf:rest rdf:nil
106 N8a8e0c6501c94920901bdfbf0bf01767 rdf:first N243a3697b8f549179be328d86b5c886e
107 rdf:rest N1db06506afcd4f5d977228c8c9477350
108 N8cd4e00255544cc0b1ab79c5a5246bc3 schema:affiliation https://www.grid.ac/institutes/grid.45203.30
109 schema:familyName Nakamura
110 schema:givenName Fumihiko
111 rdf:type schema:Person
112 N90d5193d1807446a8a95dcb20503f6b5 rdf:first N1f07c3862f46475da522441d0b96d7af
113 rdf:rest N864a578ebc774c68980434d20b23fb0a
114 N93080eda396449f08b7515f70507f4e1 schema:affiliation https://www.grid.ac/institutes/grid.411898.d
115 schema:familyName Usui
116 schema:givenName Noriko
117 rdf:type schema:Person
118 N949802c4ad814291a6b31d39b04cf0b9 rdf:first N8cd4e00255544cc0b1ab79c5a5246bc3
119 rdf:rest N2039f4a1288d44708b20bce29a70c1b4
120 N9780ecb35843487bac190108420a8c77 schema:name doi
121 schema:value 10.1007/s12185-019-02613-1
122 rdf:type schema:PropertyValue
123 N97c3699019fa4552963f846cfb142fb7 rdf:first N93080eda396449f08b7515f70507f4e1
124 rdf:rest Nc1f1920fea0e4761b1aaf47afc7f5197
125 N9fb522e0fd9b4936b3c1d6a25f0165c7 schema:affiliation https://www.grid.ac/institutes/grid.416382.a
126 schema:familyName Sumi
127 schema:givenName Masahiko
128 rdf:type schema:Person
129 Nab6a7f7d7b364eafaacb1b9d62b172f6 schema:affiliation https://www.grid.ac/institutes/grid.260969.2
130 schema:familyName Iriyama
131 schema:givenName Noriyoshi
132 rdf:type schema:Person
133 Nac31f9ae0e294aa4b705363779706182 schema:affiliation https://www.grid.ac/institutes/grid.410821.e
134 schema:familyName Inokuchi
135 schema:givenName Koiti
136 rdf:type schema:Person
137 Nb5ba568191144b0fb9e6038fb384e046 schema:familyName the New TARGET investigators
138 rdf:type schema:Person
139 Nbf1c334259304173a3a26fbfb6c8fae7 rdf:first N449601592fa147729aca84026b6215e9
140 rdf:rest N97c3699019fa4552963f846cfb142fb7
141 Nbf4f38cdce4f4946bc6f52fea435af7c rdf:first N309e85716455495fa5fbcf1899a551ac
142 rdf:rest N90d5193d1807446a8a95dcb20503f6b5
143 Nbfe1476c215949e093937a7b19f6c86d schema:affiliation https://www.grid.ac/institutes/grid.26999.3d
144 schema:familyName Kurokawa
145 schema:givenName Mineo
146 rdf:type schema:Person
147 Nc1f1920fea0e4761b1aaf47afc7f5197 rdf:first Nac31f9ae0e294aa4b705363779706182
148 rdf:rest N79fd958a6c4f4dad84eab5cf3b5ac470
149 Nc48c2a5c7c7d4e0a826156346e08a4ee schema:affiliation https://www.grid.ac/institutes/grid.410775.0
150 schema:familyName Ohnishi
151 schema:givenName Kazunori
152 rdf:type schema:Person
153 Nd3185fe611084959acdb4af9126ccb30 rdf:first Nbfe1476c215949e093937a7b19f6c86d
154 rdf:rest N11d3039ef25e457ca37c1dd21d93b41b
155 Nde1877191e034782a85f4a7b53ec5d24 schema:name dimensions_id
156 schema:value pub.1112098317
157 rdf:type schema:PropertyValue
158 Ne65173af4d4943e7a1277c08b137aca4 schema:name pubmed_id
159 schema:value 30762219
160 rdf:type schema:PropertyValue
161 Nf746cb43873842eca5928565a9d0aa06 schema:affiliation https://www.grid.ac/institutes/grid.410800.d
162 schema:familyName Yamamoto
163 schema:givenName Kazuhito
164 rdf:type schema:Person
165 Nf77bd17b90b944959621a7f1cb20761d schema:name nlm_unique_id
166 schema:value 9111627
167 rdf:type schema:PropertyValue
168 Nf8b77d805f3c4abbab4a754fec5f2647 schema:affiliation https://www.grid.ac/institutes/grid.411151.1
169 schema:familyName Kawaguchi
170 schema:givenName Tatsuya
171 rdf:type schema:Person
172 Nfd8bf465fb294b1a92b7198d40650b0a schema:name readcube_id
173 schema:value 68816fc27b947596e0dfd34708bcb759109d1ff3202696adab0faa7cc7d247ef
174 rdf:type schema:PropertyValue
175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
176 schema:name Medical and Health Sciences
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
179 schema:name Oncology and Carcinogenesis
180 rdf:type schema:DefinedTerm
181 sg:journal.1076985 schema:issn 0925-5710
182 1865-3774
183 schema:name International Journal of Hematology
184 rdf:type schema:Periodical
185 sg:pub.10.1007/s00277-018-3412-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105144477
186 https://doi.org/10.1007/s00277-018-3412-8
187 rdf:type schema:CreativeWork
188 sg:pub.10.1007/s12185-008-0186-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035994537
189 https://doi.org/10.1007/s12185-008-0186-0
190 rdf:type schema:CreativeWork
191 sg:pub.10.1007/s12185-017-2208-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084034348
192 https://doi.org/10.1007/s12185-017-2208-2
193 rdf:type schema:CreativeWork
194 sg:pub.10.1007/s12185-017-2353-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092351625
195 https://doi.org/10.1007/s12185-017-2353-7
196 rdf:type schema:CreativeWork
197 sg:pub.10.1038/leu.2012.85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006724216
198 https://doi.org/10.1038/leu.2012.85
199 rdf:type schema:CreativeWork
200 sg:pub.10.1038/leu.2016.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041273297
201 https://doi.org/10.1038/leu.2016.5
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1001/jamaoncol.2015.5932 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020032457
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/j.leukres.2010.10.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045774124
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1056/nejmoa062867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018371941
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejmoa0912614 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044250877
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1056/nejmoa1002315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031069177
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1056/nejmoa1609324 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084149625
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/annonc/mdx219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085249344
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1182/blood-2013-03-490128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037321453
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1182/blood-2013-06-511592 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024126321
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1182/blood-2014-09-594432 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008526384
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1182/blood-2016-01-694265 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021246169
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.2015.64.8899 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015564810
226 rdf:type schema:CreativeWork
227 https://doi.org/10.3109/10428194.2015.1091929 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018642418
228 rdf:type schema:CreativeWork
229 https://www.grid.ac/institutes/grid.251924.9 schema:alternateName Akita University
230 schema:name Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Akita, Japan
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.258622.9 schema:alternateName Kindai University
233 schema:name Kindai University Faculty of Medicine, Osaka-Sayama, Japan
234 rdf:type schema:Organization
235 https://www.grid.ac/institutes/grid.26091.3c schema:alternateName Keio University
236 schema:name Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
237 rdf:type schema:Organization
238 https://www.grid.ac/institutes/grid.260969.2 schema:alternateName Nihon University
239 schema:name Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
240 rdf:type schema:Organization
241 https://www.grid.ac/institutes/grid.26999.3d schema:alternateName University of Tokyo
242 schema:name Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.410775.0 schema:alternateName Japanese Red Cross Society, Japan
245 schema:name Japanese Red Cross Aichi Blood Center, Seto, Japan
246 rdf:type schema:Organization
247 https://www.grid.ac/institutes/grid.410800.d schema:alternateName Aichi Cancer Center
248 schema:name Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan
249 rdf:type schema:Organization
250 https://www.grid.ac/institutes/grid.410821.e schema:alternateName Nippon Medical School
251 schema:name Department of Hematology, Nippon Medical School, Tokyo, Japan
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.410840.9 schema:alternateName Nagoya Medical Center
254 schema:name National Hospital Organization Nagoya Medical Center, Nagoya, Japan
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.411151.1 schema:alternateName Kumamoto Health Science University
257 schema:name Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.411321.4 schema:alternateName Chiba University Hospital
260 schema:name Department of Hematology, Chiba University Hospital, Chiba, Japan
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.411898.d schema:alternateName Jikei University
263 schema:name Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.411951.9 schema:alternateName Hamamatsu University
266 schema:name Division of Hematology, Department of Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan
267 rdf:type schema:Organization
268 https://www.grid.ac/institutes/grid.412567.3 schema:alternateName Shimane University Hospital
269 schema:name Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan
270 rdf:type schema:Organization
271 https://www.grid.ac/institutes/grid.415020.2 schema:alternateName Jichi Medical University Saitama Medical Center
272 schema:name Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
273 rdf:type schema:Organization
274 https://www.grid.ac/institutes/grid.416382.a schema:alternateName Nagano Red Cross Hospital
275 schema:name Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan
276 rdf:type schema:Organization
277 https://www.grid.ac/institutes/grid.45203.30 schema:alternateName National Center For Global Health and Medicine
278 schema:name Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan
279 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...